Wall Street brokerages expect that BioLife Solutions Inc (NASDAQ:BLFS) will post earnings per share (EPS) of $0.02 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for BioLife Solutions’ earnings. BioLife Solutions reported earnings per share of $0.05 during the same quarter last year, which would suggest a negative year-over-year growth rate of 60%. The company is expected to report its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that BioLife Solutions will report full-year earnings of $0.12 per share for the current financial year, with EPS estimates ranging from $0.11 to $0.15. For the next year, analysts expect that the firm will post earnings of $0.31 per share, with EPS estimates ranging from $0.30 to $0.32. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.03. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. The business had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.67 million.

Several analysts have commented on BLFS shares. BidaskClub lowered shares of Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday, July 13th. ValuEngine upgraded shares of Vale from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Maxim Group set a $24.00 price objective on shares of BioLife Solutions and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Northland Securities raised their price objective on shares of Paycom Software from $215.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, July 9th. Finally, Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $17.80.

In other news, Director Andrew G. Hinson sold 6,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $17.19, for a total transaction of $103,140.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Walter Villiger sold 39,883 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $19.18, for a total transaction of $764,955.94. The disclosure for this sale can be found here. Insiders have sold 218,078 shares of company stock valued at $3,823,757 over the last quarter. Company insiders own 27.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Cowen Prime Services LLC purchased a new position in shares of BioLife Solutions during the first quarter valued at approximately $63,000. Signaturefd LLC purchased a new position in shares of BioLife Solutions during the first quarter valued at approximately $161,000. Conestoga Capital Advisors LLC purchased a new position in shares of BioLife Solutions during the first quarter valued at approximately $238,000. Spears Abacus Advisors LLC purchased a new position in shares of BioLife Solutions during the first quarter valued at approximately $243,000. Finally, GSA Capital Partners LLP raised its holdings in BioLife Solutions by 21.1% in the 4th quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 2,400 shares during the last quarter. Hedge funds and other institutional investors own 45.79% of the company’s stock.

Shares of BLFS opened at $17.53 on Tuesday. The company has a quick ratio of 12.99, a current ratio of 14.50 and a debt-to-equity ratio of 0.02. BioLife Solutions has a one year low of $9.15 and a one year high of $26.35. The business has a 50-day moving average of $17.13. The stock has a market capitalization of $329.55 million, a price-to-earnings ratio of 103.12 and a beta of 1.31.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.